2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2406

The Relationship Between Anti-Citrullinated Protein Antibodies and Radiographic Damage In African-Americans With Rheumatoid Arthritis
Abstract Number: 2671

The Relationship Between Toe-Out Angle During Walking and Risk Of Medial Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis Study
Abstract Number: 254

The Relationship Of Foot Pronation During Walking To Risk Of Incident Medial Tibiofemoral and Lateral Patellofemoral Cartilage Damage: The Multicenter Osteoarthritis Study
Abstract Number: 895

The Relative Risk Of Aortic Aneurysm In Patients With Giant Cell Arteritis Compared With The General Population
Abstract Number: 2539

The Reliability Of a Novel Automated System For ANA Immunofluorescence Analysis In Daily Clinical Practice
Abstract Number: 2790

The Research In Arthritis In Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Are We Achieving Clinically Important Outcomes?
Abstract Number: 2814

The Resident-Fellow Interaction: Limiting Barriers and Maximizing Learning
Abstract Number: 2897

The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study
Abstract Number: 763

The Risk Of Myocardial Infarction In Systemic Sclerosis: A Population-Based Cohort Study
Abstract Number: 376

The Risk Of Pneumococcal Infections After Immunisation With Pneumococcal Conjugate Vaccine Compared To Non-Vaccinated Inflammatory Arthritis Patients
Abstract Number: 1814

The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study
Abstract Number: 803

The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis
Abstract Number: 1998

The Risk Of Subsequent Attacks In Patients With Incident Gout: A Population-Based Study
Abstract Number: 2220

The Role Of CD11c+ Dendritic Cells In Inflammatory Arthritis
Abstract Number: 1300

The Role Of Celastrol On Osteoclastogenesis and Bone Erosion In Collagen-Induced Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].